Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M701 in Malignant Ascites Caused by Advanced Epithelial Solid Tumors
NCT06432296Phase 3Active, not recruiting
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
- Start
- Mar 2024
- Primary completion
- Aug 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of M701 in malignant ascites, sponsored by Wuhan YZY Biopharma Co., Ltd.. Started Mar 2024; status: active, not recruiting.
02
Drugs
M701
03
Conditions
malignant ascites
Beyond the preview
Go deeper on NCT06432296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06432296.